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 I was born and educated in Russia, and 
was 30 at the time of emigration to the U.S., in 
1977.  Over the last three decades, studies by 
my laboratory encompassed several fields.  
While the title of this article is about our main 
contribution to date, I describe other 
significant advances as well, in addition to new 
biochemical and genetic methods introduced 
by the lab.  A condensed summary, below, is 
followed by a more detailed account that 
places specific discoveries and inventions in 
their historical contexts. 
In 1978-79, we discovered the first 
“exposed”, nuclease-hypersensitive region in 
chromosomes (1,2).  Studies of these dynamic 
structures have become a large field, as the 
exposed regions are critical signposts of 
chromosome organization, being a part of 
transcriptional promoters, replication origins 
and other functionally important segments of 
chromatin. 
Another early work, in 1980-81, was 
the discovery of the first pathway of 
chromosome segregation, through the 
decatenation of multiply intertwined 
(multicatenated) daughter chromatids in 
replicated chromosomes (Fig. 1) (3-5).  In the 
1990s, several groups identified a 
“complementary” pathway of chromosome 
segregation, in which proteins called cohesins 
form circles around replicated chromosomes.  
Both multicatenanes (Fig. 1) and ring-shaped 
cohesins hold sister chromatids together 
through a topological confinement, in two 
entirely different ways.  The multicatenane-
mediated (3-5) and cohesin-mediated pathways 
are essential for chromosome segregation in 
mitosis and meiosis, and are closely 
coordinated, in ways that remain to be 
understood.  Acquired or inherited 
perturbations of these pathways lead to a 
decreased fidelity of chromosome segregation 
and other genomic instabilities.  These 
instabilities are among the causes of cancer. 
The third major advance, a set of 
interconnected insights between 1984 and 
1990, revealed the manifold biological 
significance of ubiquitin (Ub) conjugation and 
Ub-mediated proteolysis (Fig. 2) (6-22).  The 
field of Ub and regulated protein degradation 
was created in the 1980s, largely through the 
complementary discoveries by the laboratory 
of Avram Hershko at the Technion (Israel) and 
by my laboratory, then at MIT.  I describe 
below the elegant insights, in 1978-84, by 
Hershko and his colleagues that yielded the 
initial understanding of the Ub-mediated 
protein degradation in cell extracts, including 
the identification of E1, E2 and E3 enzymes 
(23-27). 
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These mechanistic (enzymological) 
advances were followed in 1984-90 by genetic 
and biochemical discoveries in my laboratory 
that revealed the biology of the Ub system, i.e., 
its necessity for the bulk of protein degradation 
in living cells (6,7) and its specific functions, 
in the cell cycle (6,13), DNA repair (12), 
protein synthesis (17), transcriptional 
regulation (21,22) and stress responses 
(8,10,11).  During that time, we also 
discovered the first degradation signals in 
short lived proteins (9), the first complete 
pathway of the Ub system (termed the N-end 
rule pathway) (Fig. 3) (9,14,16), the first 
specific poly-Ub chains, their bonds through 
Lys48 and Gly76 of adjacent Ub moieties, and 
the essential function of poly-Ub chains (15), 
the first physiological substrate of the Ub 
system (MATalpha2 repressor) (21,22), the 
first nonproteolytic function of Ub (its role as a 
cotranslational chaperone) (17), and the 
subunit selectivity of Ub-mediated proteolysis, 
a fundamental capability of the Ub system that 
makes possible protein remodeling (19,21).  
We also cloned the first Ub genes, discovering 
their divergent functions (8,10,11,17), as well 
as the first genes for deubiquitylating (DUB) 
enzymes and Ub-activating enzyme (28-30).  
In 1990, we identified, cloned and analyzed the 
first specific E3 Ub ligase, UBR1 (18).  This 
advance opened up a particularly large field, as 
individual mammalian genomes are now 
known to encode at least a thousand (!) Ub 
ligases.  The targeting of distinct degradation 
signals in cellular proteins by this immensity 
of E3s enables the unprecedented functional 
reach of Ub-mediated pathways.   
By revealing the fundamental and 
exceptionally broad roles of the Ub system in 
cellular physiology, our biological studies of 
1984-90 (6-22) produced the overall discovery 
of the physiological regulation by intracellular 
protein degradation.  Ramifications of this 
advance became the beginnings of several 
biomedical fields.  This discovery has also 
transformed our understanding of the logic of 
biological circuits, as it became clear that the 
control through regulated protein degradation 
rivals, and often surpasses in significance, the 
classical regulation through transcription and 
translation. 
What follows is a story of some of the 
lab’s adventures mentioned above, including 
the inventions of new biochemical and genetic 
methods.  This account stems, in part, from 
previous descriptions of the early history of the 
Ub field (31,32).  Another antecedent is an 
interview I gave to Dr. Istvan Hargittai, a 
distinguished Hungarian chemist.  It describes 
my life and science, including the early years 
in Moscow, the 1977 escape from the former 
Soviet Union, the essentially accidental hiring 
of me by MIT, and the work that ensued (33).  
The narrative below borrows from these 
sources, and mentions our more recent 
contributions as well. 
 
Beginnings 
I grew up in a scientist’s family.  So 
my interest, and later love for science, were a 
case of “nature” and “nurture” together.  My 
father Yakov Varshavsky, who is now 91 and 
lives with my mother Mary in Utah (near my 
sister’s family there), was a physical chemist 
in Moscow, where he developed methods for 
the industrial-scale production of heavy water.  
That work, a blend of fundamental and applied 
physical chemistry, was a part of Russia’s 
atomic bomb project.  In the 1950s, he became 
interested in DNA, joining other physicists and 
chemists who were leaving their fields at that 
time for the nascent world of molecular 
biology.  I was born in 1946, a year after the 
end of World War II, in a country devastated 
by it, and by the inefficiencies (let alone 
cruelties) of Stalin’s dictatorship.  Stalin died 
when I was six, and was soon denounced by 
Khrushchev, a sidekick who clawed his way to 
the top and began a less bloody rule.  In 1964, 
I was admitted as an undergraduate to the 
Chemistry Department of Moscow University.  
In 1970, I began working at Moscow’s 
Institute of Molecular Biology (IMB), in the 
laboratory headed by Georgi Georgiev.  We 
studied chromosomes and RNA, amid 
shortages of nearly everything, including good 
reagents, equipment, and contacts with 
Western researchers.  What sustained me was 
youth, love of science, and ambition – a heady 
mix.  It kept me working and hoping that 
things might improve, despite ample evidence 
to the contrary.  The time was mid-1970s, a 
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couple of years away from a chance to escape 
it all.  A convoluted path to that escape, which 
involved preparation, help from friends and a 
lot of luck, is described in ref. (33). 
I left Russia in the fall of 1977, and 
ended up in Boston-Cambridge, Massachusetts.  
A month later I was a faculty member at the 
Biology Department of the Massachusetts 
Institute of Technology (MIT), before I knew 
what exactly grants were (and before the 
colleagues who hired me became aware of that 
fact) (33).  In Moscow, I studied chromosome 
structure and regulation of gene expression.  
During my first year at MIT, I worked alone 
and continued research that began in Russia. 
I used the Simian Virus 40 (SV40) 
viral minichromosomes isolated from virus-
infected green monkey (CV1) cells as models 
of cellular chromosomes, and tried to address 
the problem of nucleosome arrangement.  
(Nucleosomes, the repeating “subunits” of 
chromosomes that comprise two superhelical 
turns of DNA wrapped around the octamer of 
histones H2A, H2B, H3 and H4, were 
discovered in 1974 by Roger Kornberg (34).)  
Were the nucleosomes distributed in a pattern 
that was specific vis-á-vis DNA sequence?  Or 
was their arrangement quasi-random, in 
addition to being dynamic?  To reduce 
potential nucleosome “sliding” (nothing was 
known about it at the time), I crosslinked the 
isolated minichromosomes with formaldehyde, 
which formed both protein-protein and protein-
DNA crosslinks.  The resulting structures were 
treated with restriction endonucleases that cut 
SV40 DNA either once or at multiple specific 
sites. 
At first I learned little, but later saw 
that one site in the minichromosome was much 
more susceptible to cleavage than any other 
site.  This “hypersensitive” site resided in a 
regulatory region that contained both the origin 
of replication and transcriptional promoters of 
SV40.  Soon thereafter, an analogous 
experiment with the endonuclease HaeIII hit 
the jackpot:  the entire ~400 bp regulatory 
region could be “excised” from the 
formaldehyde-fixed minichromosome as a 
fragment of histone-free DNA, in contrast to 
the rest of the structure, which was still an 
intramolecular aggregate (despite multiple 
HaeIII cuts in DNA), held together by 
formaldehyde-produced DNA-histone and 
histone-histone crosslinks. 
This and related advances yielded two 
insights:  the regulatory region of the SV40 
minichromosome was strikingly more 
“exposed” (more susceptible to endonuclease 
cuts) than the rest of the minichromosome;  
moreover, the nucleosomes (including 
histones) were either absent from the exposed 
region or were in a configuration that 
precluded histone-DNA crosslinks.  Our first 
results were published in 1978 (1), and a more 
detailed account in 1979 (2).  Two other 
groups, Carl Wu and Sarah Elgin at Harvard, 
and Walter Scott at the University of Florida, 
independently discovered nuclease-
hypersensitive regions in chromosomes, using 
a different approach that involved (relatively) 
nonspecific nucleases such as DNase I.  These 
discoveries became a major part of the modern 
understanding of chromosome organization, as 
later studies by many groups, including my 
lab, have shown that the exposed (nuclease-
hypersensitive) regions, which allow access to 
DNA in the otherwise tightly coiled 
chromosomal fibers, are a universal feature of 
chromosomes at replication origins, 
transcriptional promoters, and other 
functionally important sites. 
 
Discovery of the Multicatenane Pathway 
of Chromosome Segregation 
One day in the fall of 1978, I was 
reading a paper on minichromosomes, and 
noticed a faint “ladder” of bands in a pattern of 
electrophoretically fractionated SV40 DNA.  
The paper’s authors did not comment on the 
“ladder”.  At that time, Olof Sundin, a graduate 
student who recently joined the lab, began to 
study replication of the SV40 
minichromosomes and saw what appeared to 
be a similar set of bands.  Neither of us 
suspected that we were beginning a 3-year 
study that would lead, in 1980-81, to a 
fundamental discovery:  the first pathway of 
chromosome segregation (Fig. 1) (3-5). 
Briefly:  when a circular chromosome 
such as SV40 begins its replication, two 
replication forks run from the origin of 
replication in opposite directions, meeting 
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halfway around the circle and leaving behind 
two daughter minichromosomes.  Analogous 
processes take place during replication of 
cellular chromosomes, which are larger, linear, 
and contain multiple origins of replication, 
except that in this case a replication fork meets 
a fork running “toward” it from an adjacent 
origin of replication.  (In a mechanistically 
distinct but topologically equivalent model, it 
is the chromosomal fiber that moves, with 
replication forks being spatially fixed in the 
nucleus.)  These pictures of chromosome 
replication had a difficulty that wasn’t even 
recognized as a problem at that time:  how do 
the two converging replication forks (large 
structures containing polymerases, helicases 
and other proteins) replicate the last several 
hundreds of nucleotide pairs that the forks 
themselves occupy? 
We discovered that before the 
replicated SV40 daughter chromosomes 
separate from each other to yield individual 
circles, they go through a remarkable 
“topological” dance.  It begins with 
multicatenated minichromosomes, in which 
two relatively small (~5 kbp) circular 
chromatids (daughter circles) are intertwined 
around each more than 30 times!  It were the 
multicatenanes of SV40 DNA that formed 
those faint “ladders” in electrophoretic gels 
that initially attracted our attention.  The 
multicatenation stems from the in vivo 
conversion, by advancing replication forks, of 
the Watson-Crick intertwinings between two 
single strands of the parental DNA double 
helix into the topologically equivalent (but 
geometrically distinct) intertwinings of two 
double helices of the daughter circles.  This 
insight revealed the first pathway of 
chromosome segregation (Fig. 1) (3-5).  
Multicatenanes were a new form of double-
stranded DNA at the time, as only singly 
intertwined DNA circles were detected before 
1980.  It is possible that the multicatenanes we 
observed were formed not only at the 
termination of chromosome replication but 
during replication as well, a subtle and 
important issue that awaits further research.   
We showed that chromosome 
segregation in vivo was not a linear sequence 
of steps but a matrix of transitions that 
involved not only multicatenations and gradual 
decatenations, but also the superimposed, 
quasi-independent sealing of gapped or nicked 
DNA duplexes in sister chromatids, so that the 
final products were separate circles of the 
daughter chromosomes containing covalently 
closed DNA (Fig. 1).  As shown by Roger 
Kornberg in 1974 (34), the bulk of DNA in 
vivo is wrapped around histone octamers in the 
nucleosomes.  Because of this and other 
structural confinements of DNA, chromosomes 
in which the DNA is nicked or gapped in 
living cells are conformationally similar to 
their covalently closed counterparts.  In 
contrast, the isolated, histone-free DNA circles 
are relaxed in vitro if they contain a nick or a 
single-stranded gap but supercoiled if they are 
covalently closed, since the latter form of 
DNA cannot dissipate its torsional strain 
through rotation of the double helix (Fig. 1).  
The disposition with linear chromosomes is 
fundamentally the same, except that the 
number of replication forks is higher than two.  
Also, the topologically isolated domains 
(“loops”) of a linear chromosome are based on 
DNA-protein interactions, in contrast to DNA 
circularity in SV40.  In addition to the 
discovery of the multicatenane segregation 
pathway, our 1980-81 Cell papers (3,4) 
introduced new, two-dimensional 
electrophoretic methods for analyzing DNA 
replication intermediates, including 
multicatenanes.  These methods made the 
discovery possible, and are still in use today. 
At the time of this work, type-II 
topoisomerases, which mediate the segregation 
of chromosomes, were a novelty, having been 
identified, in the form of DNA gyrase, by the 
laboratory of Martin Gellert in the late 1970s 
and characterized by his and other laboratories.  
One aspect of our contribution was that topo-II 
enzymes were now expected to be essential for 
decatenation of the multiply intertwined 
chromosomal fibers which formed during 
chromosome replication and functioned as 
segregation intermediates (3-5).  Genetic 
evidence that topo II was indeed required for 
separating chromosomes by the multicatenane 
pathway (Fig. 1) was produced around 1985, 
through a collaboration between the 
laboratories of David Botstein and James 
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Wang (35), and independently by Mitsuhiro 
Yanagida (36) and Rolf Sternglanz (37).  In 
1982, Goto and Wang showed that purified 
topo II could catalyze both decatenation and 
unknotting of duplex DNA rings (38).  In 
1984, Steck and Drlica isolated a temperature-
sensitive mutant of DNA gyrase in E. coli, and 
demonstrated a double-nucleoid chromosome-
segregation arrest of this mutant at 
nonpermissive temperature (39).  These and 
other findings showed that the multicatenane 
segregation pathway (Fig. 1) was present and 
essential in all organisms, from bacteria to 
yeast and mammals. 
In the 1981 paper on chromosome 
segregation, Sundin and I proposed that the 
multicatenane pathway acts on multiply 
intertwined sister chromatids in ways that are 
likely to be controlled spatially, i.e., separately 
at specific regions such as, for example, the 
centromere versus the arms of a chromosome, 
and temporally as well, i.e., at specific stages 
of mitosis and meiosis (4).  Recent work (refs. 
(40-48) and refs. therein), including the 
evidence for a decatenation checkpoint, 
strongly supports these early conjectures, and 
has revealed several (still incompletely 
understood) interactions between the 
multicatenane pathway (Fig. 1) and other 
processes, including checkpoints that monitor 
the completion of specific steps in the cell 
cycle.  As one would expect, the multicatenane 
pathway and its aberrations are relevant to 
human diseases and their therapies.  For 
example, topo-II inhibitors are prominent 
among anticancer drugs (49), while BRCA1, a 
major tumor suppressor, plays a role in 
chromosome decatenation (50). 
The multicatenane pathway of 
chromosome segregation (Fig. 1) formally 
suffices to account for the sister chromatids 
staying together until their multiple catenations 
have been resolved, stepwise, by 
topoisomerase II during mitosis or meiosis.  
Nevertheless, a different, “complementary” 
system was identified during the 1990s that 
achieves a similar topological purpose through 
a distinct mechanism.  The second segregation 
pathway, mediated by proteins termed 
cohesins, was discovered and analyzed by 
several groups, particularly those of Douglas 
Koshland, Kim Nasmyth, Mitsuhiro Yanagida 
and Tatsuyo Hirano, with contributions by 
other labs as well.  These findings included the 
identification of multisubunit cohesins, which 
were later shown to form circles around 
replicating chromosomes (refs. (51-55) and 
refs. therein).  In 1999, Frank Uhlmann, Kim 
Nasmyth and their colleagues in the Nasmyth 
laboratory discovered a critical aspect of the 
cohesin pathway:  a protease, termed separase, 
cleaved SCC1, a specific subunit of cohesin, 
and thereby allowed the separation of sister 
chromatids (56), provided that their multiple 
intertwinings had been resolved by the 
multicatenane pathway (Fig. 1).  This brief 
description of cohesin mechanisms does not do 
justice to their intricate design and regulation 
(for example, the activation of separase is 
controlled by a specific pathway of the Ub 
system (51-55)).  There is profound 
complementarity between the multicatenane-
mediated (Fig. 1) and cohesin-mediated 
pathways of chromosome segregation.  Either 
one of the two pathways provides mechanisms 
for the adhesion and release of sister 
chromatids, yet both pathways are essential.  It 
remains to be determined, in functional and 
mechanistic detail, how the two segregation 
pathways interact.  This is an area of intense 
research, and much will be learned in the 
coming years. 
Our Ub studies, which began in 1978, 
eventually supplanted all other work in the lab.  
With reluctance and regret, I stopped working 
on chromosome segregation in 1983, and did 
not expect to return to that endeavor, which 
grew from our elucidation of the multicatenane 
segregation pathway and became a major field.  
But fate held a surprise.  In 1999, Hai Rao 
(then a postdoc) and I saw, in an article by the 
Nasmyth lab (56), that the C-terminal fragment 
of the separase-cleaved SCC1 subunit of 
cohesin bore an N-terminal arginine (Arg), 
which our previous work had shown to be a 
degradation signal in substrates of the Ub-
dependent N-end rule pathway (Fig. 3) (57).  
Rao and I decided to determine whether the 
separase-produced fragment of cohesin was 
actually short lived in vivo, and if so whether 
its degradation was functionally important.  By 
2001, in collaboration with Uhlmann and 
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Nasmyth, we demonstrated that the N-end rule 
pathway targeted cohesin’s fragment for 
degradation.  This degradation was shown to 
be essential for the proper functioning of 
cohesin machinery and the high fidelity of 
chromosome segregation, thus identifying one 
major function of the N-end rule pathway (58). 
In summary, my laboratory’s studies 
of chromosome segregation underlie the 
understanding of this fundamental process at 
three levels:  (i) through the discovery, in 
1980-81, of the multicatenane pathway of 
chromosome segregation (Fig. 1) (3-5);  
(ii) through the genetically based 1984-88 
discovery, in both yeast and mammals, that the 
Ub system is an essential part of the cell cycle 
(see below) (6,13);  and (iii) through the 
discovery, in 2001, that the degradation of the 
separase-produced fragment of cohesin by the 
N-end rule pathway is essential for high 
fidelity of chromosome segregation (58). 
Recent work by Dr. Jianmin Zhou and 
colleagues in the lab, in a collaboration with 
Dr. Debananda Pati (University of Texas, 
Houston), has shown that the function of the 
N-end rule pathway in high-fidelity 
chromosome segregation, first observed with 
the yeast S. cerevisiae (58), is relevant to 
multicellular eukaryotes as well1.  We 
employed the previously constructed (by Dr. 
Yong Tae Kwon and colleagues in the lab 
(59)) mouse strains that lacked the ATE1-
encoded Arg-tRNA-protein transferase 
(R-transferase).  The latter is a component of 
the N-end rule pathway that arginylates the 
N-terminal Asp, Glu or (oxidized) Cys 
residues of N-end rule substrates, thereby 
making them “recognizable” by Ub ligases of 
this pathway (Fig. 3).  The absence of 
R-transferase is lethal in mice:  
ATE1-/- embryos die in mid-gestation, with 
cardiovascular and other defects (59).  In both 
ATE1-/- embryos and ATE1-/- fibroblasts, the 
normally short lived (separase-produced) 
fragment of the RAD21/SCC1 subunit of 
cohesin was shown to become a long lived 
protein1.  This result is in agreement with the 
inference, from findings by the laboratory of 
Jan-Michael Peters (60), that in humans, mice 
and other mammals the cleavage of 
RAD21/SCC1 by separase would be expected 
to produce fragments that bear N-terminal Glu, 
a substrate of R-transferase (Fig. 3). 
Fittingly, our examination of ATE1-/- 
fibroblasts showed them to exhibit much 
higher chromosome instability than their +/+ 
counterparts1, a phenotype similar to that of a 
S. cerevisiae mutant that lacks the N-end rule 
pathway (58).  The identity of a key residue 
that becomes the N-terminal residue upon the 
cleavage of cohesin by separase is not 
conserved in evolution.  For example, this 
(eventually N-terminal) residue is Arg in S. 
cerevisiae but Glu in mammals.  Remarkably, 
however, in all eukaryotes examined this 
residue is a destabilizing one in the N-end rule 
(Fig. 3), indicating the importance of 
maintaining, during evolution, a short in vivo 
half-life of the cohesin fragment.  Because this 
fragment was found to interact with the rest of 
cohesin complex (58), one explanation of the 
demonstrated importance of “proactively” 
destroying the cohesin fragment (presumably 
directly on chromosomes) is that its 
spontaneous dissociation from the rest of 
cohesin may be too slow for the optimal 
kinetics of cohesin functioning.  A decade 
before our findings with cohesin (58), Erica 
Johnson (then a graduate student), David 
Gonda (then a postdoc) and I discovered that 
the N-end rule pathway can selectively destroy 
just one subunit of an oligomeric protein while 
sparing the other subunits (19).  The subunit-
selective degradation of cohesin’s fragment is 
the first example of protein remodeling by the 
N-end rule pathway.  More generally, 
regulated cleavages by nonprocessive 
proteases (e.g., separases) can produce 
destabilizing N-terminal residues in subunits of 
specific protein complexes (e.g., cohesins 
(58)).  These subunits (their C-terminal 
fragments) would then be targeted by the 
N-end rule pathway for processive degradation 
in a subunit-selective manner, i.e., modifying 
an oligomeric protein without destroying it. 
 
Discovery of Regulation by Intracellular 
Protein Degradation and Its Major 
Roles in Cellular Physiology 
 I began working at MIT in the fall of 
1977, shortly after leaving the former Soviet 
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Union.  The libraries, which I loved in Russia, 
were just as quiet and pleasant in Cambridge 
as in Moscow, and a library at MIT soon 
became my second home.  Reading there, I 
came across a curious paper, by Ira Godknopf 
and Harris Busch (61).  They found a DNA-
associated protein that had one C-terminus but 
two N-termini, an unprecedented structure.  
The short arm of that Y-shaped protein was 
joined, through its C-terminus, to an internal 
Lys residue of histone H2A, a component of 
nucleosomes.  The short arm was soon shown 
by others to be Ub, a 76-residue protein of 
unknown function that had been identified (as 
a free protein) in 1975. 
I became interested in that first Ub 
conjugate, Ub-H2A.  A few years earlier, 
while still in Russia, I began to develop a 
method for high-resolution analysis of 
nucleosomes that was based on gel 
electrophoresis of DNA-protein complexes at a 
low ionic strength (62,63).  At MIT, Louis 
Levinger (then a postdoc) and I developed this 
method further by adding electrophoresis in 
the second dimension (64,65).  A sufficiently 
long first-dimension gel separated 
mononucleosomes into three subspecies.  
Besides a ~150 bp fragment of DNA and 
histones H2B, H3 and H4, these subspecies 
contained, respectively, two molecules of 
histone H2A, one molecule each of H2A and 
Ub-H2A, or two molecules of Ub-H2A (66).  
Fractionated mononucleosomes were 
dissociated in situ and electrophoresed in the 
second dimension through an SDS-containing 
gel, followed by Southern hybridization with 
DNA probes for a region of interest (64).  In 
1982, we applied this new technique to 
Drosophila nucleosomes, and discovered that a 
transcribed gene such as HSP70 was greatly 
enriched in nucleosomes that contained one or 
two molecules of Ub-H2A, whereas the 
centromeric heterochromatin (specifically its 
regions containing the 1.688 satellite DNA) 
was completely devoid of ubiquitylated 
nucleosomes (65). 
These 1982 findings, 2 years prior to 
our genetic papers that initiated the biological 
understanding of the Ub system (6-22), were 
the first evidence bearing on the physiological 
functions of both Ub and modified histones.  
Years later, in the current field of histone 
modifications, ubiquitylated histones H2A or 
H2B are a part of fascinating patterns that 
include not only ubiquitylation but also 
acetylation, methylation, sumoylation, ADP-
ribosylation and citrullination of specific 
histones.  All or most of these changes are 
reversible in vivo.  Histone modifications are 
“read” by chromatin-associated proteins of 
many kinds, including enzymes that modify 
histones as a function of their previous 
modification states and specific locations in 
chromosomes.  Our mapping of Drosophila 
nucleosomes 26 years ago, and the conclusion 
(based on HSP70-versus-heterochromatin data) 
that ubiquitylation of histones plays a role in 
transcriptional regulation (65), are in 
agreement with insights by several recent 
studies (ref. (67) and refs. therein). 
 In the late 1970s, Avram Hershko, his 
graduate student Aaron Ciechanover and their 
colleagues in the Hershko laboratory at the 
Technion were studying ATP-dependent 
protein degradation in extracts from rabbit 
reticulocytes.  In 1978, they discovered that a 
small protein, termed APF-1 (ATP-
dependent proteolytic factor 1), was covalently 
conjugated to proteins before their degradation 
in the extract (23).  In 1980, they suggested 
that APF-1 linked to a protein served as a 
signal for a downstream protease (24), and 
began dissecting the enzymology of APF-1 
conjugation.  In 1981-84, Hershko and 
coworkers identified a set of three enzymes 
involved, termed E1 (Ub-activating enzyme), 
E2 (Ub carrier protein or Ub-conjugating 
enzyme) and E3 (an accessory component that 
appeared to confer specificity on E2) (25,26).  
The ATP-dependent protease which mediates 
the processive degradation of Ub-protein 
conjugates (27) was characterized by several 
laboratories much later, in the 1990s, and is 
now called the 26S proteasome (for recent 
reviews of the proteasome, see refs. (68,69)). 
Although our studies of Ub began in 
1978, I did not know about APF-1 results by 
Hershko and coworkers, as the identity of 
APF-1 and Ub was unknown, at that time, to 
them as well.  This changed in 1980, when 
APF-1 and Ub were shown to be the same 
protein (70), by Keith Wilkinson, Michael 
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Urban and Arthur Haas, who worked in the 
laboratory of Irwin Rose, a collaborator of 
Hershko during his stays at Philadelphia’s Fox 
Chase Cancer Center.  When I read the 1980 
paper of Hershko et al. that described the 
APF-1 conjugation to proteins in reticulocyte 
extracts (24) and the paper of Wilkinson et al. 
that described the identity of APF-1 and Ub 
(70), two previously independent realms – 
protein degradation and ubiquitylated 
nucleosomes – came together for me, 
suggesting a regulatory system of great 
complexity and broad, still to be discovered 
biological functions.  I decided to find genetic 
approaches to the entire problem, because a 
system of such complexity was unlikely to be 
understood through biochemistry alone.  In 
1980, reverse-genetic techniques were about to 
become feasible with S. cerevisiae, but were 
still a decade away in mammalian genetics.  I 
kept reading, as widely as I could.  Near the 
end of 1980, I came across a brief paper by M. 
Yamada and colleagues that described a 
conditionally lethal, temperature-sensitive 
mouse cell line called ts85.  The researchers 
showed that a specific nuclear protein 
disappeared from ts85 cells at elevated 
temperatures (71), and suggested that this 
protein may be Ub-H2A.  Glancing at their 
data, I had to calm down to continue reading, 
being virtually certain that the protein was 
Ub-H2A:  in the preceding two years we had 
learned much about electrophoretic properties 
of this Ub conjugate.  On the hunch that mouse 
ts85 cells might be a mutant in a component of 
the Ub system, I wrote to Yamada and 
received from him, in 1981, both ts85 and the 
parental (“wild-type”) cell line. 
Daniel Finley, then a graduate student, 
joined my lab at that time to study regulation 
of gene expression.  He did not need much 
convincing to switch to ts85 cells.  A few 
months into the project, Finley and I made the 
critical observation that Ub conjugation in an 
extract from ts85 cells was temperature-
sensitive, in contrast to an extract from 
parental cells.  While this was going on, I met 
Ciechanover, who came from the Hershko 
laboratory in Israel for a postdoctoral stint at 
MIT and was studying growth factor receptors 
in the laboratory of Harvey Lodish.  Presuming 
that Ciechanover was still interested in Ub 
(very few people were), I told him about our 
results with ts85 cells, and invited him to join, 
part-time, Finley and me to complete the ts85 
study.  Ciechanover joined us, the work 
continued, and in 1984 we published two 
papers that described two logically 
independent discoveries (6,7):   
1.  Mouse ts85 cells have a 
temperature-sensitive (ts) Ub-activating (E1) 
enzyme; 
2.  These cells, in contrast to parental 
cells, stop degrading the bulk of their short 
lived proteins at nonpermissive temperature. 
 This was the first evidence that Ub 
conjugation was required for protein 
degradation in vivo.  (The earlier studies by 
Hershko and coworkers were carried out with 
extracts from reticulocytes.)  Our results (6,7) 
also explained the disappearance of Ub-H2A 
from ts85 cells at nonpermissive temperature:  
thermal inactivation of the mutant (ts) Ub-
activating enzyme in these cells stops the de 
novo formation of Ub-H2A, while pre-existing 
Ub-H2A is gradually deubiquitylated by DUB 
enzymes.  (In a paper published in 1983 (72), 
Yamada and coworkers confirmed their initial 
conjecture about the identity of Ub-H2A as a 
protein that disappeared from ts85 cells, but 
pinpointed neither the cause of this effect (a ts 
E1 enzyme), nor – most importantly – the 
crucial property of these cells:  the inability, at 
nonpermissive temperature, to degrade 
proteins that are normally short lived.) 
Our discoveries with ts85 cells (6,7) 
also indicated that Ub conjugation was 
essential for cell viability, the first hint of the 
enormous, many-sided biological importance 
of the Ub system.  In addition, ts85 cells were 
preferentially arrested in the G2 phase of the 
cell cycle, and the synthesis of heat-stress 
proteins was strongly induced in these cells at 
the nonpermissive temperature (in contrast to 
parental cells), suggesting that Ub conjugation 
was involved in cell cycle progression and 
stress responses (6,7).  Although these 
conclusions about specific functions of the Ub 
system proved correct, they were still 
preliminary in 1984, given the limitations of 
mammalian somatic cell genetics.  We 
decided, therefore, to turn to S. cerevisiae, 
 8
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on August 22, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
where such issues could be addressed more 
rigorously.  As described below, our 1987-88 
discoveries with the yeast RAD6, CDC34 and 
UBI4 proteins (10,12,13) produced the first 
specific and definitive evidence that the Ub 
system is of central importance for both cell 
cycle progression and stress responses, thus 
validating the indirect evidence with ts85 cells.  
In 1983, the laboratory of Tim Hunt, a pioneer 
in studies of the cell cycle, identified unusual 
proteins in sea urchin and clam embryos.  
These proteins, which he called cyclins, were 
degraded at the end of mitosis (73).  We 
suggested in 1984 that cyclins were destroyed 
by the Ub system (6,7), a hypothesis shown to 
be correct in 1991, by Michael Glotzer, 
Andrew Murray and Marc Kirschner (74), and 
independently by Hershko and coworkers (75). 
 It may be helpful to place the above 
advances in historical context.  Despite some 
evidence to the contrary, until the 1984 Cell 
papers about mouse ts85 cells (6,7) and our 
subsequent genetic discoveries with S. 
cerevisiae, the prevailing view was that 
intracellular protein degradation was a simple 
and even mundane process, serving largely to 
dispose of “aged” or otherwise damaged 
proteins.  Cellular regulation was believed to 
be a separate affair, mediated primarily by 
repressors and activators of gene expression, 
which were assumed, often tacitly, to be long 
lived.  Among the reasons for this lopsided 
perspective was the difficulty in connecting the 
long-recognized proteolytic system in the 
lysosomes to specific pathways of intracellular 
regulation.  Thus, most people studying gene 
expression in the 1960s and 1970s assumed 
that the regulatory circuits they cared about did 
not involve short lived proteins.  As we now 
know, just the opposite proved true, especially 
in eukaryotes, where most regulators of 
transcription are short lived proteins whose 
levels in a cell are determined at least as much 
by the rates of their Ub-dependent destruction 
as by the rates of their synthesis.  Given the 
presumed stability of transcriptional regulators, 
it is ironic that the first physiological (as 
distinguished from artificial) substrate of the 
Ub system was MATalpha2, a transcriptional 
regulator that Mark Hochstrasser (then a 
postdoc) and I demonstrated in 1990 to be a 
short lived protein in vivo (21). 
 In addition to having been a 
breakthrough that indicated the requirement of 
the Ub system for intracellular proteolysis, the 
ts85 papers were also the first to address the in 
vivo workings of this system.  In 2004, this 
pair of papers (6,7) was selected for re-
publication by the editors of Cell as being 
amongst the most important papers that have 
been published in Cell’s 30-year history.  In a 
review accompanying re-publication, the late 
Cecile Pickart, one of early pioneers in the Ub 
field, summed up the papers’ contribution:  
“The two papers ... led to a new worldview:  
not only was the ubiquitin/proteasome pathway 
a major proteolytic mechanism in the average 
mammalian cell, but it was also likely to 
regulate cell cycle progression.  These 
conclusions are so well accepted today that it 
is difficult to appreciate the magnitude of their 
impact at the time the two papers appeared” 
(76). 
 In 1983, even before the ts85 work 
was completed, Finley, Engin Özkaynak (then 
a postdoc) and I, together with other 
colleagues in the lab, began a systematic 
analysis of the Ub system in the genetically 
tractable S. cerevisiae (Fig. 2), a project that 
soon expanded to occupy the entire laboratory.  
Between 1983 and 1990, this work revealed 
the first specific biological functions of Ub 
conjugation and discovered the first 
degradation signals in short lived proteins.  
Briefly mentioned below are key advances of 
those early years that established the 
physiological fundamentals of the Ub field. 
 Polyubiquitin Gene and Resistance to 
Stress – In 1984, Özkaynak, Finley and I 
cloned the first Ub gene.  Unexpectedly, it 
encoded not a single Ub moiety but a head-to-
tail poly-Ub precursor protein (8).  By 1987, 
we showed that this gene, UBI4, was strongly 
induced by a variety of stresses, and that a 
deletion of UBI4 resulted in hypersensitivity to 
these stresses (10,11).  (ubi4Δ cells were viable 
under normal conditions, as they still contained 
other Ub genes.)  These genetically based 
results validated and deepened our earlier 
indirect evidence with mouse ts85 cells (6), 
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thus identifying stress responses as one 
important and broad function of the Ub system. 
 First Degradation Signals in Short 
Lived Proteins – In 1986, Andreas Bachmair 
(then a postdoc), Finley and I discovered, 
through the invention of the Ub fusion 
technique, specific degradation signals that 
target proteins for Ub conjugation and 
proteolysis, including the set of signals that 
give rise to the N-end rule of protein 
degradation (9).  By identifying the first 
“primary” degradation signals in short lived 
proteins, this advance solved the fundamental 
problem of the source of selectivity in Ub 
conjugation.  “Primary” degradation signals 
are specific features of proteins that make them 
substrates for Ub-conjugating enzymes, called 
Ub ligases.  (In most settings, Ub itself is a 
“secondary” signal for proteolysis, in that Ub 
is conjugated to a protein that contains a 
“primary” degradation signal.)  The N-end rule 
relates the in vivo half-life of a protein to the 
identity of its N-terminal residue (9,14).  The 
underlying N-end rule pathway (Fig. 3) was 
the first of two specific pathways of the Ub 
system to be discovered, years before a 
multitude of other Ub-dependent pathways 
came into view. 
The Ubiquitin Fusion Degradation 
(UFD) Pathway – The second pathway of the 
Ub system, which we later termed the UFD 
(Ub fusion degradation) pathway, was 
identified in 1986, simultaneously with the 
N-end rule (9), and was subsequently 
characterized by Erica Johnson, Bonnie Bartel 
(then graduate students) and myself (77,78).  
The UFD pathway was shown to target for 
degradation a subset of Ub fusions in which 
the N-terminal Ub moiety could not be cleaved 
off in vivo by DUB enzymes either at all or 
fast enough (9,77,78).  An impediment to 
cleavage by DUB enzymes can be a Pro 
residue at the Ub-protein junction (9) or an 
alteration of Ub structure.  Retention of the 
N-terminal Ub moiety was shown to result in 
the recognition of this moiety as a “primary” 
degradation signal by Ub ligases of the UFD 
pathway (77,78).  Studies of this pathway, 
particularly by Stefan Jentsch and colleagues 
(e.g., ref. (79)), are now an active and 
important field. 
The N-end Rule Pathway in 
Prokaryotes – The functional and mechanistic 
understanding of the N-end rule pathway 
(Fig. 3) eventually became a major focus of 
my laboratory.  In 1991, John Tobias (then a 
graduate student), Thomas Shrader (then a 
postdoc) and I extended the use of the Ub 
fusion technique (9) to a prokaryote such as E. 
coli.  We discovered that although E. coli 
lacked the Ub system, it still had the N-end 
rule pathway (80), a Ub-independent one.  In 
contrast to many physiological functions of the 
eukaryotic N-end rule pathway that were 
identified over the last decade, the physiology 
of prokaryotic N-end rule pathways remains an 
enigma. 
 Terminology for Degradation Signals 
– The term “degron”, a shorthand for 
“degradation signal”, was suggested in 1991 
and gradually became a standard notation (81).  
The N-terminal degrons of the N-end rule 
pathway (Fig. 3) are called N-degrons (81).  
One advantage of “degron” – a mnemonic and 
compact term – is that it can denote any 
specific degradation signal through the use of 
informative prefixes, superscripts or 
subscripts.  For example, an N-degron 
containing a specific destabilizing N-terminal 
residue such as Arg (R), would be called 
NR-degron. 
Specific Determinants of Degradation 
Signals – In 1989, Bachmair and I carried out 
the first dissection of a Ub-dependent 
degradation signal, and found that an N-degron 
consisted of three essential determinants:  a 
destabilizing N-terminal residue of a protein 
substrate (Fig. 3);  at least one of substrate’s 
internal Lys residues (the site of formation of a 
poly-Ub chain);  and a conformationally 
flexible region in the vicinity of the relevant 
Lys residue (14).  A decade later, Tetsuro 
Suzuki (then a postdoc) and I extended this 
analysis by showing that highly active and 
specific N-degrons can be produced by 
employing sequences that comprise just two 
residues, Asn or Lys, and selecting for 
N-degrons through a genetic screen in the 
Lys/Asn sequence space (82).  The 
multi-determinant organization of N-degrons 
recurs in other (subsequently identified) 
degradation signals, which differ to a large 
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extent by the nature of their first determinant, 
the one that is initially recognized by a specific 
E3 Ub ligase.  In N-degrons, this determinant 
is a destabilizing N-terminal residue (Fig. 3), 
whereas in a degron targeted by other Ub-
dependent pathways it can be, for example, an 
internal sequence motif.  By revealing the 
basis of specificity of intracellular protein 
degradation, the 1986 discovery of the UFD 
degron and N-degrons (9) has founded the 
field of degradation signals.  This is a major 
arena at present, because a number of distinct, 
often conditional degrons in the multitude of 
cellular proteins can be targeted by specific 
and exquisitely controlled E3s of the Ub 
system. 
N-Terminal Arginylation – In the late 
1960s and early 1970s, Kaiji and Soffer 
(83,84) identified a new reaction, the 
N-terminal arginylation of intracellular 
proteins, by the enzyme Arg-tRNA-protein 
transferase (R-transferase).  In the 1986 paper 
about the first degradation signals in short 
lived proteins, we proposed that R-transferase 
and N-terminal arginylation are, most likely, a 
part of the N-end rule pathway (Fig. 3) (9).  
This suggestion pinpointed the previously 
enigmatic biological function of 
R-transferases, identifying them as a part of a 
proteolytic system (9).  Both our later work 
(16) and the 1987 study by Ferber and 
Ciechanover (85) confirmed the above 
conjecture (9).  In 1990, Mordechai Choder 
(then a postdoc in the lab) collaborated with 
the laboratory of Andrea Goffeau (University 
of Louvain, Belgium) to identify and clone the 
yeast ATE1 gene, encoding R-transferase (20).  
More recent work with mammalian 
R-transferases (59,86-90) is described below. 
RAD6, DNA Repair and the Ubiquitin 
System – In 1987, Stefan Jentsch (then a 
postdoc), John McGrath (then a graduate 
student) and I discovered that RAD6, a protein 
known to yeast geneticists as an essential 
component of DNA repair pathways, is a 
Ub-conjugating (E2) enzyme, the first 
Ub-conjugating enzyme with a specific 
physiological function (12).  In addition to 
discovering that the Ub system is required for 
DNA repair, we noticed that the sequence of 
RAD6 was weakly similar to that of CDC34, 
an essential cell cycle regulator (of unknown 
biochemical activity) that had been defined 
genetically in S. cerevisiae by Lee Hartwell 
and had been shown by him to be required for 
the G1-S phase transition in the cell cycle. 
CDC34, the Ubiquitin System and the 
Cell Cycle – To verify the exciting possibility 
that CDC34 may be a distinct Ub-conjugating 
enzyme, Jentsch, McGrath and I collaborated 
with Mark Goebl in the laboratory of Breck 
Byers (University of Washington, Seattle).  In 
1988, this collaboration demonstrated that 
CDC34 is indeed a specific Ub-conjugating 
(E2) enzyme (13).  This discovery was the first 
rigorous proof that the Ub system is an integral 
part of the cell cycle, a role first suggested, but 
not proven, by our 1984 study with mouse ts85 
cells (6,7).  The critical advance with CDC34 
(13) gave rise to a major field, as it became 
clear, through subsequent work by other 
groups, that proteolysis by the Ub system 
underlies biological periodicity, from the cell 
cycle to circadian rhythm oscillators.  Because 
perturbations of the cell cycle, DNA repair and 
stress response are hallmarks of cancer, our 
discoveries with RAD6, CDC34 and UBI4 
(10,12,13) opened up Ub studies in cancer 
research as well.  Other important connections 
between the Ub system and the cell cycle, 
including the 1991 demonstration, by the 
Kirschner and Hershko laboratories, that 
cyclins are substrates of the Ub system (74,75), 
took place a few years after the 1987-88 
insights with RAD6 and CDC34 (12,13). 
First Nonproteolytic Function of 
Ubiquitin – In 1987, Özkaynak, Finley and I 
cloned and analyzed S. cerevisiae UBI1-UBI3, 
the Ub genes other than the poly-Ub gene 
UBI4 (11).  In 1989, Finley, Bartel and I 
discovered the functions of UBI1-UBI3.  We 
showed that they encoded fusions of Ub to one 
protein of the large ribosomal subunit and one 
protein of the small ribosomal subunit, an 
arrangement conserved from yeast to mammals 
(17).  Genetic analyses with precursors of 
ribosomal proteins encoded by UBI1-UBI3 
indicated that the presence of Ub in front of a 
specific ribosomal protein, despite being 
transient in vivo (Ub is rapidly cleaved off by 
DUB enzymes), is required for efficient 
biogenesis of ribosomes (17).  Apart from 
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discovering a specific role of the Ub system in 
the translation apparatus and protein synthesis, 
these results showed that in certain contexts 
Ub acts not as a degradation signal but as a 
cotranslational chaperone.  This first 
nonproteolytic function of Ub (17) appeared to 
be an exceptional case until years later, when 
Linda Hicke and Howard Riezman 
demonstrated that ubiquitylation of a plasma 
membrane-embedded receptor signals its 
endocytosis (91).  Ub is now recognized to 
have numerous nonproteolytic functions.   
First Specific Polyubiquitin Chains – 
In 1989, using new approaches that included 
two-dimensional protein mapping assays, 
Vincent Chau and other colleagues in my 
laboratory demonstrated that Ub-protein 
conjugation in vivo produces a substrate-linked 
poly-Ub chain of a specific topology, with the 
isopeptide bonds between adjacent Ub 
moieties through the Lys48 residue of Ub (15).  
In contrast to linear poly-Ub precursors of Ub 
that are encoded by poly-Ub genes (see above), 
a posttranslationally produced poly-Ub chain is 
based on repeating, branch-generating 
isopeptide bonds between the adjacent Ub 
moieties in a chain.  The 1989 study also 
demonstrated that poly-Ub chains linked to 
substrates are essential for the in vivo 
degradation of these substrates (15).  We 
suggested that a major function of the poly-Ub 
chain is to bind a targeted substrate to the 
proteasome (15), a hypothesis confirmed by 
others, in part through the identification of 
poly-Ub binding proteins as components of the 
26S proteasome.  Later work has shown that 
poly-Ub chains can also be of different “local” 
topologies, with adjacent Ub moieties in a 
chain linked through Lys residues other than 
Lys48.  Most of “alternative” poly-Ub chains 
have nonproteolytic functions.  The discovery 
of specific poly-Ub chains (15) illuminated the 
mechanistic role of Ub in proteolysis, and was 
the beginning of another major field in Ub 
studies. 
First Physiological Substrate of the 
Ubiquitin System – In 1990, Hochstrasser and I 
identified the first short lived physiological 
substrate of the Ub system, the transcriptional 
repressor MATalpha2, and delineated its 
degradation signals (21,22).  Until 1990, both 
our and other studies were confined to artificial 
(e.g., genetically engineered) substrates.  The 
1990-91 MATalpha2 papers were the first (and 
definitive) evidence for the importance of the 
Ub system in transcriptional regulation.  Many 
specific roles of Ub-dependent processes in 
transcription and its control were discovered 
since 1990.  The MATalpha2 work (21,22) 
was also the beginning of insightful 
independent studies by Mark Hochstrasser that 
employed MATalpha2 both for its own sake 
and as a fulcrum to dissect specific aspects of 
the Ub system.  As mentioned above, in 1991 
the Kirschner and Hershko laboratories 
identified a mitotic cyclin as the second 
physiological substrate of the Ub system 
(74,75).  Nearly two decades later, we know 
hundreds of such substrates.  Moreover, it 
became clear that most cellular proteins, 
including those that travel through or reside in 
membrane-enclosed compartments, can 
become physiological substrates of the Ub 
system at certain stages of their in vivo 
existence. 
Subunit Selectivity of Protein 
Degradation – In 1990, Johnson, Gonda and I 
discovered that Ub-mediated protein 
degradation is subunit-selective (19).  This 
fundamental capability of the Ub system 
underlies protein remodeling, i.e., the 
replacement of specific subunits in oligomeric 
complexes of innumerable kinds.  Also in 1990, 
Hochstrasser and I detected subunit selectivity 
in the degradation of the MATaplha2 repressor, 
the first physiological substrate of the Ub 
system (21).  Subunit-selective proteolysis is a 
critical property of the Ub system, a feature 
both powerful and flexible, in that it enables 
protein degradation to be wielded as an 
instrument of protein remodeling for either 
positive or negative regulation.  Through its 
ability to make protein machines 
compositionally dynamic, the subunit 
selectivity of degradation (19,21) literally 
enables the vast physiology of Ub.  Some 
better known examples of subunit selectivity 
are the degradation of cyclin subunits in the 
CDK kinases (a process that drives the cell 
cycle oscillator), the degradation of the 
inhibitory IκB subunit in the IκB/NF-κB 
complex (a transition that activates NF-κB, a 
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major transcriptional regulator), and the 
degradation of a separase-produced cohesin 
fragment by the N-end rule pathway, a step 
that underlies the high fidelity of chromosome 
segregation (58). 
Cloning and Analysis of the First 
Specific E3 Ubiquitin Ligase – In 1990, Bartel, 
Ingrid Wünning (then a postdoc) and I 
employed genetic and biochemical approaches 
to identify, clone and analyze the first specific 
E3 Ub ligase, termed UBR1 (18).  This 
multifunctional 225 kDa protein is the sole E3 
of the S. cerevisiae N-end rule pathway.  (The 
term “Ub ligase” denotes either an E2-E3 
holoenzyme or its E3 component.)  This 
advance (18) opened up a particularly large 
field, as individual mammalian genomes are 
now known to encode at least a thousand 
distinct Ub ligases.  Through their exquisitely 
regulated targeting of specific degrons in 
conditionally or constitutively short-lived 
proteins, these E3s underlie the enormous 
functional reach of the Ub system. 
 In summary, the complementary 
discoveries in the 1980s by the Hershko and 
my laboratories revealed three sets of 
previously unknown facts: 
 1.  ATP-dependent protein degradation 
involves a new protein modification, Ub 
conjugation, which is mediated by specific 
enzymes, termed E1, E2 and E3 (23-26,31). 
 2.  The selectivity of Ub conjugation is 
determined by specific degradation signals 
(degrons) in short lived proteins, including the 
degrons that give rise to the N-end rule 
(9,14,16,18). 
 3.  Ub-dependent processes play a 
strikingly broad, previously unsuspected part 
in cellular physiology, primarily by controlling 
the in vivo levels of specific proteins.  Ub 
conjugation was demonstrated by us to be 
required for protein degradation in vivo (6,7), 
for cell viability, and also, specifically, for the 
cell cycle (6,13), DNA repair (12), protein 
synthesis (17), transcriptional regulation (21), 
and stress responses (8,10).  Ub-dependent 
proteolysis was discovered to involve a 
functionally essential, substrate-linked 
poly-Ub chain of unique topology (15).  The 
Ub system was also discovered to possess the 
fundamental property of subunit selectivity, 
i.e., the ability to destroy a specific subunit of 
an oligomeric protein while leaving the rest of 
the protein intact and thereby making possible 
protein remodeling (19). 
 The Hershko laboratory produced the 
first of these fundamental advances (item 1), 
and my laboratory produced the other two 
(items 2 and 3).  These complementary 
“chemical” and “biological” discoveries of the 
1980s caused a massive expansion of the Ub 
field in the 1990s.  It became one of the largest 
arenas in biomedical science, the point of 
convergence of many disparate disciplines.  
The work by many excellent laboratories that 
entered the Ub field over the last 15-20 years 
has revealed, among other things, the existence 
of more than ten Ub-like conjugation pathways.  
These pathways involve Ub-like proteins 
(called SUMO, NEDD8, etc.) and specific 
enzymes that are similar to the enzymes of Ub 
conjugation.  Ub-like pathways have a number 
of functions, mostly (though not exclusively) 
nonproteolytic ones.  These pathways interact 
with the Ub system, the largest one and the 
first to be characterized.  The resulting 
“meta-set” of the Ub and Ub-like systems is of 
vast size and functional sweep (for recent 
reviews, see refs. (68,69,92-101)). 
Our discovery of the physiological 
fundamentals of the Ub system (6-22) has 
yielded the modern paradigm of cellular 
physiology, in which regulated proteolysis is 
of central importance.  These advances, 
expanded through later studies by many 
groups, including my lab, have shown that the 
control through regulated protein degradation 
rivals, and often surpasses in significance, the 
classical regulation through transcription and 
translation.  This radically changed 
understanding of the logic of biological 
circuits is beginning to have a major impact on 
medicine, given the immense functional range 
of the Ub system and the multitude of ways in 
which Ub-dependent processes can 
malfunction in disease or in the course of 
aging, from cancer and neurodegenerative 
syndromes to perturbations of immunity and 
many other illnesses, including birth defects.  
A number of pharmaceutical companies are 
developing compounds that target specific 
components of the Ub system.  The fruits of 
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their labors have already become, or will soon 
become, clinically useful drugs.  Efforts in this 
arena may yield not only “conventional” 
inhibitors or activators of enzymes but also 
more sophisticated drugs that would direct the 
Ub system to target, destroy, and thereby 
downregulate any specific protein.  I feel 
privileged having been able to contribute to the 
birth of this field two decades ago and to 
partake in its later development.  The 
dynamism and surprises of this endeavor 
remain undiminished even today. 
 
Multidrug Transporters, Gene 
Amplification and AT-DNA Binding 
Proteins 
MDR1, a Multidrug Transporter – In 
1984, Igor Roninson (then a postdoc) and I 
collaborated with the laboratory of David 
Housman at MIT to identify and clone the first 
mammalian gene that encoded a major 
multidrug transporter, termed MDR1 (102).  
This transmembrane protein was the first 
member of a large family of transporters, some 
of which are induced by stress.  One function 
of MDR-type transporters is to mediate the 
export of either potentially or actually toxic 
(largely hydrophobic) compounds.  Increased 
activity and/or abundance of multidrug 
transporters in cancer cells are a major cause 
of drug resistance in cancer therapy.  By 
making possible both dissection of MDR1 and 
the cloning of other MDR-type transporters, 
the 1984 breakthrough (102) gave rise to a 
large field in cancer research. 
Induced Gene Amplification – Gene 
amplification in mammalian cells was 
discovered in 1978 by Frederic Alt and Robert 
Schimke.  In 1981, I found that growth factors 
such as hormones or tumor promoters can 
greatly increase the frequency of gene 
amplification under conditions of cytotoxic 
stress (103).  (The lab was small then, and I 
could still work at the bench.)  A follow-up 
study in 1983 with James Barsoum (then a 
graduate student) confirmed and extended 
these insights (104).  Analogous gene 
amplification events contribute to rapid 
evolution of cancer cells in a tumor, and to the 
emergence of drug-resistant cells during 
anticancer therapy.  Thea Tlsty and Robert 
Schimke independently demonstrated, also in 
1981, the same phenomenon of induced 
(accelerated) gene amplification. 
 HMG-I/Y, Datin and D1 as AT-DNA 
Binding Proteins – In the 1982 study of 
Drosophila nucleosomes that demonstrated 
their strongly preferential ubiquitylation in a 
transcribed region such as the HSP70 gene 
(65), we noticed that nucleosomes containing a 
~50 kDa protein called D1 (105) were entirely 
devoid of Ub-H2A.  Another 1982 study by 
Levinger and myself showed that D1 
preferentially binds to (A+T)-rich DNA in 
vitro, including the 1.672 and 1.688 satellite 
DNA repeats, and is a component of isolated 
nucleosomes containing these centromeric 
satellite DNAs (106).  Later studies (107,108) 
indicated that D1, which contains 10 copies of 
the “AT-hook” domain, a motif that interacts 
with the minor groove of AT-rich DNA, is a 
part of heterochromatin-associated machinery 
of transcriptional repression. 
Work on D1 increased my interest in 
AT-DNA binding proteins, in part because of 
their relevance to sequence-specific 
nucleosome arrangements in chromatin.  Our 
projects in this arena led to discoveries of two 
new proteins.  In 1984, Francois Strauss (then 
a postdoc) and I identified and purified a green 
monkey protein, eventually termed HMG-I/Y 
(its initial name was alpha-protein), that 
preferentially bound to three specific AT-rich 
sites in the nucleosome-sized DNA repeat of 
the monkey alpha-satellite DNA (109).  Later 
studies by others showed that HMG-I/Y, which 
contains AT-hook domains, plays a major role 
in the assembly and function of DNA-
associated multiprotein complexes such as 
“enhancesomes”, which mediate 
transcriptional activation (ref. (107,108) and 
refs. therein). 
In 1989, Edward Winter (then a 
postdoc) and I searched for AT-DNA binding 
proteins in yeast, and identified a 248-residue 
protein, named datin, that exhibited a highly 
specific binding to DNA containing oligo(dA)-
oligo(dT) tracts (110).  Such tracts are 
common in the intergenic regions of S. 
cerevisiae and other organisms.  The discovery 
of datin was our last contribution to 
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chromosome research for many years to come:  
by that time, Ub studies supplanted all other 
work in the lab. 
 
New Biochemical and Genetic Methods 
A scientific study is constrained by the 
quality and sophistication of its tools.  Hence 
my lifelong interest in new methods.  I 
mentioned the development, by Sundin and 
myself, of two-dimensional electrophoretic 
techniques for analyzing DNA replication 
intermediates.  These methods made possible 
the discovery of the multicatenane pathway of 
chromosome segregation (Fig. 1) (3-5) and are 
still in use today. 
Low Ionic Strength Gel 
Electrophoresis and Gel Shift Assay – In 1975, 
when I was still in Russia, my colleagues and I 
introduced a method for gel electrophoresis in 
buffers of low (~10 mM) ionic strength 
(62,63).  Decreased levels of counterions 
increased both stability and mutual repulsion 
of, for example, negatively charged 
nucleoprotein complexes, and thereby greatly 
reduced their aggregation during 
electrophoresis.  In a 1976 application of this 
technique, the forerunner of the gel shift assay, 
we employed it to fractionate isolated 
nucleosomes at a previously unattainable 
resolution (63).  In 1981, the laboratories of 
Donald Crothers (111) and Arnold Revzin 
(112) independently employed a similar 
nondenaturing electrophoresis, termed later the 
gel shift assay (113), to detect and measure the 
interactions of specific DNA-binding proteins, 
such as the Lac repressor, with their cognate 
DNA operators.  In 1984, Strauss and I 
demonstrated that this assay, until then used 
exclusively with purified proteins, can detect 
specific DNA-binding proteins in the presence 
of nonspecifically binding ones, provided that a 
sample contains a sufficient excess of 
“nonspecific” DNA (109).  This elaboration of 
gel shift assay made possible the detection of 
sequence-specific DNA-binding proteins in 
crude cell extracts.  It soon became, and 
continues to be, one of the most widely 
practiced procedures in chromosome research. 
Chromatin Immunoprecipitation Assay 
(ChIP) – In 1988, Mark Solomon (then a 
graduate student), Pamela Larsen (then a 
postdoc) and I introduced the chromatin 
immunoprecipitation (ChIP) assay (114).  In 
this technique, intact cells are covalently (and 
extensively) “fixed” with a crosslinking 
reagent such as formaldehyde, followed by 
disruption of the fixed cells, fragmentation of 
their chromosomes, and immunoprecipitation 
of crosslinked chromatin fragments with an 
antibody to a protein of interest.  Subsequent 
thermal reversal of crosslinks makes possible 
the identification (through hybridization or 
DNA sequencing) of specific genomic sites 
that are bound, in vivo, to a protein of interest 
under different physiological conditions.  
Since 1988, the ChIP assay (114) (it was 
named “ChIP” by later users of this method) 
became a major, strikingly versatile tool in 
chromosome research.  One of many examples 
is the central role of ChIP assays in studies on 
the functions of histone modifications.  The 
use of formaldehyde, both in our 1978-79 
discovery of the first “exposed” region in 
chromosomes (1,2) and in the 1988 invention 
of the ChIP assay (114), stemmed from my 
earlier chromosome studies in Russia (115). 
Hypersensitivity to Heavy Water, a 
New Conditional Phenotype – One of our last 
“non-Ub” contributions in the 1980s was the 
invention, by Bartel and myself, of a new way 
to make conditional mutants (116).  Although 
temperature-sensitive (ts) mutants were a 
mainstay of genetic analysis for decades, my 
first encounters with them, in the early 1980s, 
suggested that this approach could stand an 
improvement.  One problem is the leakiness of 
ts mutants, i.e., nonzero activity of a ts protein 
at nonpermissive temperature.  In addition, 
producing a ts version of a protein of interest 
is, in many cases, an iffy affair that requires 
extensive mutagenesis.  Might there be other, 
also generally applicable, types of conditional 
mutants?  Might there be a perturbant as 
pervasive as temperature?  One evening in 
1986, I realized that the answer may be yes:  
heavy water!  (My father’s studies of D2O in 
the 1950s and my recollection of his work 
were the likely impetus of that thought.)  
Biologically, D2O would be indistinguishable 
from H2O in all respects except toxicity.  The 
idea was simplicity itself:  determine a 
maximum concentration of D2O that is still 
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compatible with a near-normal growth of an 
organism of interest, such as yeast.  Thereafter 
mutagenize the cells and carry out a screen for 
mutants that are hypersensitive to D2O, i.e., for 
mutants (we called them ds, D2O-sensitive) 
that cannot grow at a concentration of D2O that 
is still nontoxic to wild-type cells.  If such 
mutants can be obtained, straightforward 
assays can be used to determine whether most 
of the organism’s essential genes can be 
mutated to a conditionally lethal ds phenotype.  
I did preliminary experiments that suggested 
the ds technique may be feasible.  Bonnie 
Bartel got interested in this approach, and soon 
demonstrated that yeast ds mutants could be 
easily produced, and that apparently any or 
almost any gene could be mutated to a ds 
allele.  Moreover, we found that most ds 
mutants were not ts, and vice versa.  In other 
words, the ds and ts techniques tapped entirely 
different sets of mutant alleles.  Although the 
ds method (116) is technically straightforward 
and possibly superior to ts in some settings, the 
ts technique is still the predominant approach, 
in part because of its comparative ease and 
familiarity.  As described below, yet another 
technique for producing conditional mutants, 
invented by us in 1994 (117), proved to be 
more in tune with current trends in genetics. 
Ubiquitin Fusion Technique – In 1986, 
Bachmair, Finley and I invented the Ub fusion 
technique, which led to the discovery of the 
N-end rule pathway (9).  DNA-encoded linear 
Ub fusions to other proteins mimic natural Ub 
fusions that are encoded by Ub genes (10,11).  
Ub fusions were found to be cotranslationally 
cleaved at the Ub-protein junction by DUB 
enzymes irrespective of the identity of a 
residue at the junction’s C-terminal side, with 
proline (Pro) being a single exception (9,14).  
The resulting Ub-fusion approach, in which 
site-directed mutagenesis is used to alter a 
residue at the Ub-protein junction, is still the 
method of choice for placing, in vivo, a desired 
residue at the N-terminus of a protein of 
interest (9,118).  The requirement for a 
“technique” to do this stems from constraints 
of the genetic code, as all nascent proteins start 
with Met.  Met-aminopeptidases (MetAPs) 
would cleave off the N-terminal Met only if a 
residue at position 2, to be made N-terminal 
after cleavage, has a small enough side chain 
(118).  Hence the necessity of a “bypass” 
method to alter N-terminal residues at will in 
vivo (9).  Over the last two decades, several 
descendants of the Ub fusion technique were 
developed in the lab: 
Ubiquitin Reference Technique – This 
1996 method, by Frédéric Lévy (then a 
postdoc), other colleagues in the lab and 
myself, utilizes Ub fusion constructs encoding 
both a protein of interest and a “reference” 
protein, with the two proteins cotranslationally 
coexpressed at (initially) equimolar levels 
(118,119).  Through a “built-in” reference 
protein, this method greatly increases the 
accuracy of pulse-chase assays (82,120). 
Heat-Activated Degron (ts-Degron) – 
This 1994 method, by Jürgen Dohmen, Pei Pei 
Wu (then postdocs) and myself, allows one to 
produce ts alleles of specific proteins without 
the (usually necessary) random mutagenesis, 
and without altering a protein’s amino acid 
sequence (117).  The method involves a 
“pre-designed”, portable N-degron that can be 
activated by increased temperature.  A protein 
of interest is linked to such a degron, and 
becomes short lived in vivo at the 
nonpermissive temperature (117).  In contrast 
to our under-utilized D2O (ds) technique for 
making conditional mutants (116), the 
ts-degron method (117) is widely employed by 
other laboratories, in a range of projects, as an 
alternative to conventional ts mutants. 
Ubiquitin Translocation Technique – 
This 1994 method, by Nils Johnsson (then a 
postdoc) and myself, allows one to probe, in 
vivo, kinetic aspects of protein translocation 
across membranes (121).  A fusion in which 
the Ub moiety is placed between a signal 
sequence and a reporter domain is cleaved by 
DUB enzymes in the cytosol unless the fusion 
can “escape” into a compartment such as the 
endoplasmic reticulum (ER).  The critical step 
involves rapid folding of the newly formed Ub 
moiety, which precludes its translocation and 
makes possible the cleavage by DUBs after its 
last residue.  However, if a sufficiently long 
spacer is present between the signal sequence 
and Ub, then by the time the Ub polypeptide 
emerges from the ribosome and is ready to 
fold, the ribosome is already docked at the 
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transmembrane channel, allowing the 
translocation of both the Ub moiety and the 
downstream reporter domains of a fusion into 
the ER.  These mutually exclusive outcomes 
make it possible to probe, by varying the 
length of spacer and other parameters, both 
kinetic and stochastic aspects of targeting in 
protein translocation, and to compare the 
strengths of different signal sequences in vivo.  
This method (121) is also applicable to non-ER 
translocation. 
Split-Ubiquitin Assay for In Vivo 
Protein Interactions – This 1994 method, by 
Johnsson and myself (122), made possible both 
the detection of a protein-protein interaction 
and its monitoring as a function of time, at the 
natural sites of this interaction in living cells.  
(The latter feature of the split-Ub technique is 
one of its advantages over methods such as the 
classical two-hybrid assay, where interacting 
protein domains must “make” it to the nucleus 
and transcriptional-promoter settings.)  We 
found that when a ~40-residue C-terminal half 
(Cub) of the 76-residue Ub was expressed as a 
fusion to a reporter protein, the fusion was 
cleaved only if the N-terminal half (Nub) of Ub 
was also expressed in the same cell, implying 
that the two halves coalesced in vivo to 
produce a quasi-native Ub moiety, thereby 
allowing the cleavage by DUBs at the 
Ub-reporter junction.  This reconstitution of 
quasi-native Ub from its fragments was not 
observed with a specifically (mutationally) 
altered Nub half of Ub.  However, if Cub and the 
altered Nub were each linked to polypeptides 
that interacted in vivo, the cleavage of the 
reporter fusion containing Cub was restored.  
This approach yielded a generally applicable 
assay for in vivo protein interactions (122).  
One difference between the split-Ub method 
and the earlier alpha-complementation with 
LacZ (β-galactosidase) (123) is that the latter 
assay involves reconstitution of an oligomeric 
protein through contacts between its subunits 
(or their derivatives) that were separate 
molecules to begin with, whereas split Ub is a 
split single-domain protein.  Several variants 
of the split-Ub assay were developed after 
1994 and employed to dissect specific protein 
interactions in vivo or to screen for new 
interactions (refs. (124-126), and refs. therein).  
The invention of the split-Ub technique (122) 
gave rise to the field of protein fragment 
complementation assays (PCAs) and a number 
of useful designs that include split 
dihydrofolate reductase (DHFR) (127) and 
split green fluorescent protein (GFP) (128). 
Ubiquitin Sandwich Technique – 
“Cotranslational degradation” refers to 
destruction of a polypeptide in vivo while it is 
still a part of a ribosome-associated 
peptidyl-tRNA.  How to detect and measure 
such degradation?  In the 2000 Ub sandwich 
technique by Glenn Turner (then a graduate 
student) and myself (129), the polypeptide to 
be examined for cotranslational degradation, 
termed B, is sandwiched between two reporter 
domains, A and C.  The A, B and C domains 
are connected by Ub moieties, yielding a linear 
AUb-BUb-CUb fusion.  DUB enzymes 
cotranslationally cleave this fusion, generating 
AUb, BUb, and CUb.  After the initial 
cleavage at the AUb-BUb junction, the activity 
of DUBs results in a kinetic competition 
between two mutually exclusive fates during 
the synthesis of AUb-BUb-CUb:  
cotranslational cleavage at the BUb-CUb 
junction, which produces the long-lived CUb 
module, or, alternatively, cotranslational, 
processive degradation of the entire BUb-CUb 
nascent chain by the proteasome that destroys 
the Ub moiety between B and C before it can 
be recognized by DUBs.  The resulting drop in 
levels of CUb relative to AUb reflects the 
presence and extent of cotranslational 
degradation of domain B (129).  Using this 
method, we found that more than 50% of 
nascent protein molecules bearing an N-degron 
can be degraded cotranslationally, never 
reaching their mature size before their 
destruction by processive proteolysis (129).  
Thus, the folding of nascent proteins, including 
abnormal ones, may be in kinetic competition 
with pathways that target these proteins for 
degradation cotranslationally. 
 
Recent Studies 
Our current focus is the N-end rule 
pathway.  We study it in fungi (S. cerevisiae), 
mammals (M. musculus), and in prokaryotes 
such as E. coli and the human pathogen Vibrio 
vulnificus.  This work led to discoveries of the 
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pathway’s functions in eukaryotes, but not in 
prokaryotes, thus far.  Despite recent advances 
in the mechanistic dissection of bacterial 
N-end rule pathways (80,130-133), their 
biological roles are unknown.  Our studies of 
the mouse N-end rule pathway were led by 
Dr. Yong Tae Kwon, who now works in his 
own laboratory at the University of Pittsburgh.  
Thus far, Yong Tae’s and my labs are the only 
ones that focus on the N-end rule pathway. 
 The N-end rule has a hierarchic 
structure (Fig. 3).  In eukaryotes, N-terminal 
Asn and Gln are tertiary destabilizing residues 
in that they function through their enzymatic 
deamidation, to yield the secondary 
destabilizing N-terminal residues Asp and Glu 
(134,135).  Destabilizing activity of N-terminal 
Asp and Glu requires their conjugation to Arg, 
one of the primary destabilizing residues, by 
ATE1-encoded R-transferases (Fig. 3).  In 
1999, Kwon, Anna Kashina (then a postdoc) 
and I cloned mouse ATE1 and found that it 
encodes at least 2 splicing-derived isoforms of 
R-transferase (86).  In 2006, Rong-Gui (Cory) 
Hu, Christopher Brower (postdocs in the lab) 
and their colleagues identified and 
characterized 6 splicing-derived isoforms of 
mouse R-transferase (88). 
In mammals and other eukaryotes that 
produce nitric oxide (NO), the set of 
arginylated N-terminal residues contains not 
only Asp and Glu but also N-terminal Cys (16), 
which is arginylated after its oxidation to 
Cys-sulfinate or Cys-sulfonate (Fig. 3), as 
shown in 2002 by Kwon, Kashina, Hu, Ilia 
Davydov (then a postdoc), Fangyong Du (then 
a graduate student) and myself (59).  In 2005, 
Hu, Jun Sheng (then a postdoc) and I 
discovered that the in vivo oxidation of 
N-terminal Cys requires NO, as well as 
oxygen (O2) or its derivatives (Fig. 3) (87).  
The N-end rule pathway is thus a sensor of NO, 
through the ability of this pathway to destroy 
proteins with N-terminal Cys, at rates 
controlled by NO, O2 and their derivatives.  
This work also identified G-protein regulators 
RGS4, RGS5 and RGS16 as conditionally 
short lived proteins that are targeted by the 
arginylation branch of the N-end rule pathway 
through their (conditionally oxidized) 
N-terminal Cys (87).  The Kwon laboratory 
independently showed that RGS4, RGS5 and 
RGS16 are physiological N-end rule substrates 
(90).  (In 2000, Davydov and I found that 
RGS4 was degraded by the N-end rule 
pathway in reticulocyte extracts (136), before 
we knew that this degradation requires NO and 
oxygen (87,90).)  Through the conditional 
degradation of RGS4, RGS5 and RGS16, the 
N-end rule pathway regulates G proteins and 
thus the signaling by transmembrane receptors. 
 An N-degron is produced from 
pre-N-degron through a proteolytic cleavage. 
MetAPs proteases remove Met from the 
N-terminus of a newly formed protein only if 
the residue at position 2, to be made 
N-terminal after cleavage, has a small enough 
side chain.  Consequently, of the 13 
destabilizing residues in the mammalian N-end 
rule (Fig. 3), only Cys can be made N-terminal 
by MetAPs (87).  Individual mammalian 
genomes encode ~250 proteins with Cys at 
position 2, i.e., the proteins that would be 
expected to contain N-terminal Cys in vivo.  
Thus RGS4, RGS5, and RGS16, the currently 
known N-end rule substrates of this class, are 
but a small subset of other potential N-end rule 
substrates whose conditional degradation 
would be regulated by NO and oxygen.  Note 
that any destabilizing residue, including Cys, 
can be made N-terminal through internal 
cleavages of proteins by other proteases, such 
as separases, caspases and calpains (Fig. 3).  In 
other words, the above “~250” is an upper 
limit only for those N-terminal Cys-bearing 
proteins that are produced by MetAPs.  There 
is no upper limit on the number of potential 
N-end rule substrates that may be produced by 
other proteolytic cleavages in cellular proteins. 
In S. cerevisiae, the N-terminal 
amidase NTA1 (it was identified, cloned and 
analyzed in 1995 by Rohan Baker, then a 
postdoc in the lab) (134) mediates deamidation 
of N-terminal Asn and Gln, converting them 
into Asp and Glu, the substrates of 
R-transferase.  In multicellular eukaryotes, the 
deamidation branch of the N-end rule pathway 
bifurcates:  a distinct N-terminal amidase, 
NTAN1, is specific for N-terminal Asn, 
whereas another amidase (it remains to be 
identified) deamidates N-terminal Gln (Fig. 3).  
In 1996, Sergei Grigoryev (then a postdoc) and 
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colleagues in the lab collaborated with the 
laboratory of Ralph Bradshaw (University of 
California, Irvine) to clone and characterize the 
mouse NTAN1 amidase (137).  The biological 
role of yeast NTA1 remains to be discovered, 
as nta1Δ S. cerevisiae, which lack N-terminal 
deamidation, have no discernible abnormal 
phenotypes other than their inability to degrade 
reporter N-end rule substrates with N-terminal 
Asn or Gln (134).  In contrast, NTAN1-/- mice, 
which lack the Asn-specific N-terminal 
deamidation, are behaviorally abnormal (135). 
E3 Ub ligases of the N-end rule 
pathway, called N-recognins (57), recognize 
(bind to) primary destabilizing N-terminal 
residues (Fig. 3).  At least four N-recognins, 
including UBR1, underlie the N-end rule 
pathway in mammals (138-141).  In S. 
cerevisiae, the N-end rule pathway is mediated 
by a single 225 kDa N-recognin, UBR1 (18), 
which functions in a complex with RAD6, a 
Ub-conjugating (E2) enzyme (57,142).  UBR1 
contains at least three substrate-binding sites, 
which were identified and dissected over the 
years by colleagues in the lab, most recently by 
Zanxian Xia, Ailsa Webster, Michel Ghislain 
(then postdocs), Konstantin Piatkov (a postdoc 
in the lab), Du and myself (143).  The type-1 
site of UBR1 is specific for basic N-terminal 
residues of protein substrates (Arg, Lys, His), 
while the type-2 site is specific for bulky 
hydrophobic N-terminal residues (Trp, Phe, 
Tyr, Leu, Ile) (Fig. 3).  The third binding site 
of UBR1 targets proteins through their internal 
(non-N-terminal) degrons. 
What might be a physiological (and 
evolutionary) rationale for the multiplicity of 
substrate-binding sites in a single E3 protein 
that results in it recognizing both N-degrons 
and non-N-degrons?  The function of this 
design of UBR1 was discovered in 1998-2002, 
by Turner, Du, Christopher Byrd (then a 
graduate student) and myself (120,144,145).  
In 1998, Byrd, Turner and I identified the yeast 
transcriptional repressor CUP9 as a short lived 
substrate of the N-end rule pathway and a 
downregulator of PTR2, which encodes the 
major transporter of short peptides (144).  This 
result explained the earlier finding, by the 
laboratory of Jeffrey Becker (University of 
Tennessee, Knoxville), that the import of 
peptides in S. cerevisiae stops in the absence of 
UBR1 (146).  In 2000-02, Turner, Du and I 
discovered that the degradation of CUP9 is 
conditional:  the third substrate-binding site of 
UBR1, which targets CUP9 through its internal 
degron, is autoinhibited, and is allosterically 
activated through a conformational change that 
is caused by the binding of short peptides 
(bearing destabilizing N-terminal residues) to 
the other two (type-1 and type-2) binding sites 
of UBR1 (120,145).  The resulting reversal of 
UBR1 autoinhibition by imported peptides 
accelerates the UBR1-dependent ubiquitylation 
of CUP9, leading to its faster degradation, 
lower steady-state levels and consequently a 
derepression of the transporter-encoding PTR2 
gene (120,145).  This positive-feedback circuit, 
mediated by short peptides, allows cells to 
detect the presence of extracellular peptides 
and to react by increasing their uptake. 
 In 2008, Hu, Haiqing Wang (then a 
postdoc), Xia and I discovered that the N-end 
rule pathway is a sensor of heme (89).  
Low-micromolar levels of hemin (Fe3+-heme) 
inhibit arginylation by the ATE1 R-transferase 
in both yeast and mammals (Fig. 3).  In 
addition, hemin induces the proteasome-
mediated degradation of R-transferase in vivo.  
Thus, remarkably, hemin acts as both a 
“stoichiometric” and “catalytic” downregulator 
of the N-end rule pathway.  This proteolytic 
system, a sensor of short peptides, NO and 
oxygen, is now a sensor of heme as well (89).  
One function of the N-end rule pathway may 
be to coordinate the activities of effectors, both 
reacting to and controlling the redox dynamic 
of heme, oxygen, NO and thiols, in part 
through the conditional degradation of specific 
transcription factors (e.g., CUP9) and 
regulators of G proteins (e.g., RGS4, RGS5 
and RGS16). 
 Between 1996 and 2003, Yong Tae 
Kwon and colleagues in my lab constructed 
and analyzed mouse strains that lacked specific 
components of the N-end rule pathway (Fig. 3), 
such as NTAN1 (Asn-specific N-terminal 
amidase), ATE1 (R-transferase), UBR1 (one of 
mouse N-recognins), and UBR2 (another 
N-recognin) (59,135,138,147).  These studies, 
and our later collaboration with Yong Tae’s 
laboratory have revealed informative 
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phenotypes of mouse mutants that further 
expanded the functional range of the N-end 
rule pathway.  Its currently known functions 
include the sensing of heme, NO, oxygen, and 
short peptides;  maintenance of the high 
fidelity of chromosome segregation;  
regulation of signaling by transmembrane 
receptors, through control of the activity of 
specific G proteins;  regulation of apoptosis;  a 
multitude of processes mediated by the 
transcription factor c-FOS, a conditional 
substrate of the N-end rule pathway;  
regulation of the human immunodeficiency 
virus (HIV) replication cycle;  regulation of 
meiosis, spermatogenesis, neurogenesis and 
cardiovascular development in mammals, and 
regulation of leaf senescence in plants (refs. 
(58,59,87,89,90,138,140,147-150) and refs. 
therein).  In 2005, a collaborative study with 
Yong Tae Kwon’s and my labs that was led by 
Dr. Martin Zenker’s laboratory at the 
University of Erlangen-Nuremberg (Germany) 
showed that mutations in human UBR1 
(Fig. 3) are the cause of Johansson-Blizzard 
Syndrome (JBS), which comprises mental 
retardation, physical malformations, and 
severe pancreatitis (150).  The abnormalities of 
the previously constructed UBR1-/- mice (147) 
include pancreatic insufficiency (150), a less 
severe counterpart of this defect in human JBS 
(UBR1-/-) patients.   
 Despite their multiplicity and broad 
range, the known functions of the N-end rule 
pathway are the tip of the iceberg.  Several 
fascinating phenotypes of mouse N-end rule 
mutants remain to be understood.  One 
example:  NTAN1-/- mice, which lack the 
Asn-specific N-terminal deamidation (Fig. 3), 
are fertile, do not exhibit gross abnormalities, 
and are seemingly indistinguishable from their 
+/+ littermates (135).  However, behavioral 
tests with NTAN1-/- mice revealed significant 
perturbations in their spontaneous activity, 
spatial memory, and social behavior (135).  
Discovering the relevant physiological N-end 
rule substrates would be essential for 
identifying circuits that are perturbed in 
NTAN1-/- mice, and the same is true for other, 
more overt defects, in other mouse N-end rule 
mutants and in human JBS patients. 
In 2000, Youming Xie (then a postdoc) 
and I discovered that UBR1 (the E3 of the 
N-end rule pathway) and UFD4 (the E3 of the 
UFD pathway) interact with specific proteins 
of the 19S regulatory particle of the 26S 
proteasome (151).  In addition to the 
possibility that these interactions underlie a 
route for delivery of ubiquitylated substrates to 
the proteasome, our results suggested that at 
least some Ub ligases may target their 
substrates while in a complex with the 26S 
proteasome.  Other groups soon reported that 
several other Ub ligases also interacted with 
the 26S proteasome.  In 2002, Xie and I 
showed that a mutant UFD4 Ub ligase that 
lacked its proteasome-binding region could 
still mediate ubiquitylation of UFD substrates 
but their proteolysis was impaired, strongly 
suggesting that the proteasome-UFD4 
interaction is functionally relevant (152). 
 In 2002, Sheng and I dissected the 
degradation signal of c-MOS, a kinase and 
regulator of oocyte maturation and (153).  Data 
by other groups suggested that the N-terminal 
Pro residue of c-MOS (it becomes N-terminal 
after removal of N-terminal Met by MetAPs) 
was a destabilizing residue that targeted c-
MOS for destruction in frog oocytes.  Our 
degradation assays involved microinjection of 
plasmids that expressed wild-type or mutant 
c-MOS in Xenopus oocytes.  We showed that, 
contrary to the above interpretation of earlier 
data, the N-terminal Pro residue of c-MOS is 
dispensable for c-MOS degradation if the Ser-
2 residue (encoded Ser-3) of c-MOS is 
replaced by a small nonphosphorylatable 
residue such as Gly.  The dependence of 
c-MOS degradation on N-terminal Pro turned 
out to be caused by a Pro-mediated 
downregulation of the net phosphorylation of 
Ser-2, a modification that halts c-MOS 
degradation.  Thus, N-terminal Pro is not a 
recognition determinant for an N-recognin E3.  
In sum, and in agreement with our earlier 
evidence, Pro is, operationally, a stabilizing 
residue in the N-end rule (153). 
In 2004, I proposed two terms, 
sequelog and spalog (154), to address a 
disconnect between high rigor of statistical 
methods for comparing sequences or structures 
and the often logically unjustified employment 
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of assumption-laden terms “homolog”, 
“ortholog” and “paralog”.  The new terms, 
“sequelog” and “spalog”, denote, respectively, 
a sequence that is similar, to a specified extent, 
to another sequence, and a three-dimensional 
structure that is similar, to a specified extent, 
to another three-dimensional structure (154).  
Besides their usefulness as separate terms for 
sequence versus spatial similarities, the 
rigor-conferring advantage of “sequelog” and 
“spalog” is their evolutionary neutrality, in 
contrast to often unproven evolutionary links 
implied by “homolog”, “ortholog” and 
“paralog”.  The latter terms are compatible 
with the sequelog/spalog terminology and can 
be employed to convey understanding about 
functions and common descent, if this 
(additional) information is available.  Helpful 
derivatives of, for example, “sequelog” are 
sequelogy (sequence similarity) and 
sequelogous (similar to another sequence).  
Spalog and sequelog fill a lacuna in the 
existing terminology.  These terms would 
clarify and streamline discourses about 
similarity (154). 
 
New Approaches to Therapy 
 A subject that I am particularly 
interested in are multitarget, conditional drugs, 
devices that “think” before they “decide” to act.  
The coming revolution in medicine will 
involve not only qualitatively better ways to do 
surgery but also drug-based therapies that will 
take into account, at last, the massive 
interconnectedness and redundancy of 
molecular circuits in living cells.  Single-
compound (and even multi-compound) drugs 
of today are incapable of such finesse.  
Therefore even otherwise useful drugs exhibit 
undesirable side effects.  Yet another problem 
is our continuing helplessness in containing 
(let alone curing) major human cancers once 
they spread beyond a surgeon’s knife.  The 
problem is exacerbated by genomic instability 
of many, possibly most, cancers.  This 
property increases heterogeneity of malignant 
cells in the course of tumor progression or 
anticancer treatment and is one reason for the 
failure of most cancer therapies.  A few 
relatively rare cancers can often be cured 
through chemotherapy but require cytotoxic 
treatments of a kind that cause severe side 
effects and are themselves carcinogenic.  
Recent advances, including the use of 
antiangiogenic compounds and inhibitors of 
specific kinases, hold the promise of curative 
therapies.  Nevertheless, major human cancers 
are still incurable once they have metastasized. 
In 1995, I suggested a design of 
protein-based “multitarget” reagents based on 
multiple degrons and their conditional masking 
by specific cellular proteins (155).  A 1998 
paper described another design, of small 
compounds whose activity can be modulated 
by more than one protein ligand at the same 
time (156).  We eventually decided not to 
implement these approaches in the lab, because 
I thought, perhaps mistakenly, that the 
resulting drugs would not be efficacious 
enough in a clinical setting.   
In 2007, I proposed a new approach to 
cancer therapy that involves homozygous 
DNA deletions (157).  Such deletions are 
present in many (possibly most) cancers, and 
differ from any other attribute of a cancer cell 
by the fact that an HD cannot revert.  Hence 
the idea of a treatment that homes exclusively 
on cells that lack specific DNA sequences that 
are present in normal cells.  If this proves 
possible, a resulting therapy may be entirely 
specific for cancer cells, and thus not only 
curative but substantially free of side effects as 
well.  The difficulty here is that a homozygous 
deletion is an “absence”, and therefore it 
cannot be a conventional molecular target.  
Nevertheless, an HD-specific regimen is 
feasible, on paper so far (157).  This strategy, 
termed deletion-specific targeting (DST), 
employs HDs – not their effects on 
RNA/protein circuits but deletions themselves 
– as the targets of cancer therapy.  The DST 
strategy brings together, in a novel way, both 
existing and new methodologies, including the 
Ub fusion technique, the split-Ub assay, zinc-
finger DNA-recognizing proteins and split 
restriction nucleases.  The DST strategy also 
employs a new feedback mechanism that 
receives input from a circuit operating as a 
Boolean OR gate and involves the activation of 
split nucleases, which destroy the DST vector 
in normal (non-target) cells.  The logic of DST 
makes possible an incremental and essentially 
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unlimited increase in the selectivity of 
treatment (157). 
If the substantial complexity of 
DST-type strategies is unavoidable (that 
remains to be determined), approaches of this 
kind might be a harbinger of therapies to come.  
The virtues of simplicity notwithstanding, a 
complex problem, such as an assured cure of 
cancer, or a selective elimination of damaged 
(e.g., aged) mitochondria in cells of a patient, 
or other such feats may require 
commensurately sophisticated solutions.  Can 
small compounds, with their inherently low 
informational content, ever enable a definitive 
cure of cancer that is free of collateral 
damage?  The notion that underlies (and 
motivated) the DST strategy (157) is that a 
curative, side effects-free treatment may 
require polymer-scale, multitarget, 
Boolean-type circuits, i.e., that simpler 
(smaller) drugs may ultimately not suffice, 
particularly in regard to side effects.  The task 
at hand is to address the validity of this 
assumption.  Work on the DST strategy is 
under way in the lab. 
 
Epilog 
My laboratory has been at Caltech for 
the past 16 years.  The decision to move here 
from MIT was prompted by an unexpected 
invitation.  I showed it to my wife Vera, and 
we visited Caltech in February 1991.  The 
scientific quality of Caltech, the charms of 
Pasadena’s subtropical climate, and warm 
reception by colleagues were compelling to 
both of us.  Caltech is a great place, similar to 
MIT in all respects but smaller.  Vera and I 
live in La Canada, a hamlet on a mountainside 
near Pasadena. 
At 61, I have already traveled through 
the bulk of lifespan allotted to us by evolution.  
Curiously, the Ub system plays a major role in 
determining that lifespan.  Moreover, 
Ub-dependent processes underlie just about 
everything a living cell does.  An account of 
our discoveries through which this fact became 
known and understood is the main chapter of 
this recollection. A scientist’s life – its 
adventures and misadventures, its loves and 
conflicts – is largely incidental, tangential to 
one’s contribution, in a profession that tends to 
swallow a person whole.  Our propensity to be 
curious about other people obscures the fact 
that it is essentially immaterial that Isaac 
Newton was not a kind man, or that Johannes 
Kepler had to defend his mother in court 
against the charge of being a witch (she was 
acquitted).  To think of Newton or Kepler is to 
think of their work.  The same applies to all of 
us in this remarkable guild, irrespective of the 
scale of one’s accomplishment. 
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Legends to Figures 
 
FIGURE 1.  The multicatenane-
mediated pathway of chromosome segregation 
(3-5).  Thick horizontal arrows denote 
pathways of DNA synthesis that convert 
gapped or nicked DNA circles into covalently 
closed circles.  Thin vertical arrows denote 
pathways of decatenation of daughter 
chromosomes.  Daughter DNA duplexes are in 
blue and red, while parental DNA is in green.  
The monomeric (completely decatenated) 
daughter circles are also in green, as they 
become parental DNA in the next round of 
replication (red arrow).  The A, B and C 
notations of multicatenated DNA dimers 
correspond, respectively, to both circles 
relaxed (nicked or gapped), one circle 
covalently closed (and therefore supercoiled), 
and both circles covalently closed.  Numbers 
in, e.g., A10-A30 are catenation linking 
numbers, i.e., the extents of intertwining of 
double helices in the topologically linked 
circles.  The theta structures (replication 
intermediates) in parentheses are diagrams of 
thetas in which the parental (green) DNA is 
nicked (and therefore relaxed).  The indicated 
multicatenanes such as B5, C3, C5, etc. are not 
depicted explicitly, given their highly 
“entangled” configurations as histone-free 
DNA.  Among the technical innovations in 
these 1980-81 (3-5) studies was the discovery 
that hypertonic treatment of SV40-infected 
green monkey CV1 cells arrested replicated 
chromosomes at the stage of decatenation.  
During arrest, highly intertwined nicked (or 
gapped) form-A multicatenanes were 
eventually converted (via B-form 
intermediates) to the equally highly 
intertwined C-form multicatenanes (C10-C30), 
in which both circles were covalently closed 
and supercoiled (thick dashed arrows at the 
top).  The supercoiled state stemmed from the 
presence of nucleosomes in the 
minichromosomes, prior to removal of 
histones for analyses of DNA topology.  Upon 
release from the decatenation block, the highly 
intertwined C-form multicatenanes were 
decatenated to supercoiled monomers (vertical 
dashed arrows;  “recovery pathway”).  The 
actual paths taken during chromosome 
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segregation (in the absence of decatenation 
arrest) include the entire matrix of transitions 
shown in the diagram.  The relative rates of 
flow along specific paths depend on the rates 
of gap-filling DNA synthesis (converting a 
nicked or gapped circle into a covalently 
closed circle) versus the rates of decatenation 
of multiply intertwined chromosomes by 
topoisomerase II (3,4). 
 
 FIGURE 2.  The ubiquitin (Ub) system 
of the yeast S. cerevisiae.  The fundamental 
design of this system is conserved among 
eukaryotes.  The yeast Ub genes UBI1-UBI4, 
two of which contain introns, encode fusions 
of Ub either to itself or to one of two 
ribosomal proteins.  These fusions are cleaved 
by deubiquitylating enzymes (DUBs), yielding 
mature Ub.  Thioester bonds between Ub and 
the active-site Cys residues of Ub-specific 
enzymes are denoted by the “~” sign.  The 
conjugation of Ub to other proteins involves a 
preliminary ATP-dependent step, in which the 
last (Gly76) residue of Ub is joined, via a 
thioester bond, to a Cys residue of the Ub-
activating (E1) enzyme, encoded by UBA1.  
The activated ubiquitin is transferred to a Cys 
residue in one of several Ub-conjugating (E2) 
enzymes, encoded by the UBC-family genes, 
and from there to a Lys residue of an ultimate 
acceptor protein.  E2 enzymes function as 
subunits of E2-E3 Ub ligase holoenzymes.  
The functions of E3 include the initial 
recognition of a substrate’s degradation signal 
(degron) and the E2/E3-mediated 
polyubiquitylation of the substrate (black 
ovals).  The names of some among 
approximately 200 E3s of S. cerevisiae are 
indicated as well.  A targeted, ubiquitylated 
protein is processively degraded to short 
peptides by the ATP-dependent 26S 
proteasome. 
 
 FIGURE 3.  The mammalian N-end 
rule pathway.  N-terminal residues are 
indicated by single-letter abbreviations for 
amino acids.  Yellow ovals denote the rest of a 
protein substrate.  A notation, upward of 
“hemin” in the middle of diagram, is a 
modified “downregulation” sign that denotes, 
specifically, a downregulation mediated, at 
least in part, by target’s degradation.  MetAPs, 
methionine aminopeptidases.  C* denotes 
oxidized Cys, either Cys-sulfinate or Cys-
sulfonate, produced in reactions mediated by 
nitric oxide (NO), oxygen (O2) and their 
derivatives.  Oxidized N-terminal Cys is 
arginylated by ATE1-encoded isoforms of 
R-transferase.  Type-1 and type-2 primary 
destabilizing N-terminal residues are 
recognized by the pathway’s E3 Ub ligases, 
called N-recognins.  Through their other 
substrate-binding sites, these E3s also 
recognize internal (non-N-terminal) degrons in 
other substrates of the N-end rule pathway, 
denoted by a larger oval.  See the main text for 
details. 
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